{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:17:46Z","timestamp":1790612266921,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Familial hypercholesterolemia (FH) is one of the most common autosomal dominant diseases. FH causes a lifelong increase in low-density lipoprotein cholesterol (LDL-C) levels, which in turn leads to atherosclerotic cardiovascular disease. The incidence of FH is widely underestimated and undertreated, despite the availability and effectiveness of lipid-lowering therapy. Patients with FH have an increased cardiovascular risk; therefore, early diagnosis and treatment are vital. To address the burden of FH, several countries have implemented national FH screening programmes. The currently used method for FH detection in Lithuania is mainly based on opportunistic testing with subsequent cascade screening of index cases\u2019 first-degree relatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 428 patients were included in this study. Patients with suspected FH are referred to a lipidology center for thorough evaluation. Patients who met the criteria for probable or definite FH according to the Dutch Lipid Clinic Network (DLCN) scoring system and\/or had LDL-C\u2009&gt;\u2009=\u20096.5 mmol\/l were subjected to genetic testing. Laboratory and instrumental tests, vascular marker data of early atherosclerosis, and consultations by other specialists, such as radiologists and ophthalmologists, were also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 127\/428 (30%) patients were genetically tested. FH-related mutations were found in 38.6% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200949\/127) of the patients. Coronary artery disease (CAD) was diagnosed in 13% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957\/428) of the included patients, whereas premature CAD was found in 47\/428 (11%) patients. CAD was diagnosed in 19% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099\/49) of patients with FH-related mutations, and this diagnosis was premature for all of them.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most patients in this study were classified as probable or possible FH without difference of age and sex. The median age of FH diagnosis was 47 years with significantly older females than males, which refers to the strong interface of this study with the LitHir programme. CAD and premature CAD were more common among patients with probable and definite FH, as well as those with an FH-causing mutation. The algorithm described in this study is the first attempt in Lithuania to implement a specific tool which allows to maximise FH detection rates, establish an accurate diagnosis of FH, excluding secondary causes of dyslipidaemia, and to select patients for cascade screening initiation more precisely.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-024-02124-x","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T08:02:04Z","timestamp":1715068924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Algorithm for detection and screening of familial hypercholesterolemia in Lithuanian population"],"prefix":"10.1186","volume":"23","author":[{"given":"Urte","family":"Aliosaitiene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaneta","family":"Petrulioniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidija","family":"Rinkuniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antanas","family":"Mainelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egle","family":"Brazdziuniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urte","family":"Smailyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaida","family":"Sileikiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandras","family":"Laucevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"crossref","unstructured":"Singh S, Bittner V. Familial Hypercholesterolemia\u2014Epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2).","DOI":"10.1007\/s11883-014-0482-5"},{"key":"2124_CR2","doi-asserted-by":"crossref","unstructured":"Zuurbier LC, Defesche JC, Wiegman A. Successful genetic screening and creating awareness of familial hypercholesterolemia and other heritable Dyslipidemias in the Netherlands. Genes (Basel). 2021;12(8).","DOI":"10.3390\/genes12081168"},{"issue":"32","key":"2124_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"4","key":"2124_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ehjqcco\/qcx011","volume":"3","author":"G Villa","year":"2017","unstructured":"Villa G, Wong B, Kutikova L, Ray KK, Mata P, Bruckert E. Prediction of cardiovascular risk in patients with familial hypercholesterolaemia. Eur Hear J - Qual Care Clin Outcomes. 2017;3(4):274\u201380.","journal-title":"Eur Hear J - Qual Care Clin Outcomes"},{"key":"2124_CR5","doi-asserted-by":"crossref","unstructured":"Sullivan DR, Freeman L, Molloy L, Williams G. Screening for familial hypercholesterolaemia: Universal or Cascade? A critique of current FH Recognition Strategies. Curr Cardiovasc Risk Rep. 2015;9(2).","DOI":"10.1007\/s12170-014-0434-1"},{"issue":"20","key":"2124_CR6","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"2124_CR7","doi-asserted-by":"publisher","unstructured":"Petrulioniene Z, Gargalskaite U, Kutkiene S, Staigyte J, Cerkauskiene R, Laucevicius A. Establishing a national screening programme for familial hypercholesterolaemia in Lithuania. Atherosclerosis [Internet]. 2018;277:407\u201312. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.012.","DOI":"10.1016\/j.atherosclerosis.2018.06.012"},{"issue":"1","key":"2124_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-017-0694-z","volume":"17","author":"S Abdul-Razak","year":"2017","unstructured":"Abdul-Razak S, Rahmat R, Mohd Kasim A, Rahman TA, Muid S, Nasir NM, et al. Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population. BMC Cardiovasc Disord. 2017;17(1):1\u20138.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2124_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvaa122","volume":"5","author":"DTW Lui","year":"2021","unstructured":"Lui DTW, Lee ACH, Tan KCB. Management of familial hypercholesterolemia: current status and future perspectives. J Endocr Soc. 2021;5(1):1\u201314.","journal-title":"J Endocr Soc"},{"issue":"2","key":"2124_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MOL.0000000000000398","volume":"28","author":"I Kindt","year":"2017","unstructured":"Kindt I, Mata P, Knowles JW. The role of registries and genetic databases in familial hypercholesterolemia. Curr Opin Lipidol. 2017;28(2):152\u201360.","journal-title":"Curr Opin Lipidol"},{"issue":"45","key":"2124_CR11","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478\u201390.","journal-title":"Eur Heart J"},{"key":"2124_CR12","doi-asserted-by":"crossref","unstructured":"Peterson AL, Bang M, Block RC, Wong ND, Karalis DG. Cascade screening and treatment initiation in young adults with heterozygous familial hypercholesterolemia. J Clin Med. 2021;10(14).","DOI":"10.3390\/jcm10143090"},{"issue":"10","key":"2124_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2017-017817","volume":"7","author":"J Pang","year":"2017","unstructured":"Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, et al. An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the ten Countries Study. BMJ Open. 2017;7(10):1\u20139.","journal-title":"BMJ Open"},{"key":"2124_CR14","doi-asserted-by":"publisher","unstructured":"Louter L, Defesche J, van Roeters J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl [Internet]. 2017;30:77\u201385. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.019.","DOI":"10.1016\/j.atherosclerosissup.2017.05.019"},{"issue":"4","key":"2124_CR15","doi-asserted-by":"publisher","first-page":"e0001795","DOI":"10.1371\/journal.pgph.0001795","volume":"3","author":"C Page","year":"2023","unstructured":"Page C, Zheng H, Wang H, Rai TS, O\u2019Kane M, Hart P, et al. A comparison of the Netherlands, Norway and UK familial hypercholesterolemia screening programmes with implications for target setting and the UK\u2019s NHS long term plan. PLOS Glob Public Heal. 2023;3(4):e0001795.","journal-title":"PLOS Glob Public Heal"},{"key":"2124_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.33549\/physiolres.933600","volume":"66","author":"M Vrabl\u00edk","year":"2017","unstructured":"Vrabl\u00edk M, Vaclov\u00e1 M, Tich\u00fd L, So\u0161ka V, Bl\u00e1ha V, Fajkusov\u00e1 L, et al. Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed Project. Physiol Res. 2017;66:S1\u20139.","journal-title":"Physiol Res"},{"issue":"1","key":"2124_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/v10287-012-0003-3","volume":"18","author":"A Laucevi\u010dius","year":"2012","unstructured":"Laucevi\u010dius A, Kasiulevi\u010dius V, Jatu\u017eis D, Petrulionien\u0117 \u017d, Ryli\u0161kyt\u0117 L, Rink\u016bnien\u0117 E, et al. Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme - rationale and design. Semin Cardiovasc Med. 2012;18(1):1\u20136.","journal-title":"Semin Cardiovasc Med"},{"key":"2124_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","volume":"22","author":"AJ Vallejo-Vaz","year":"2016","unstructured":"Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS familial hypercholesterolaemia studies collaboration. Atheroscler Suppl. 2016;22:1\u201332.","journal-title":"Atheroscler Suppl"},{"key":"2124_CR19","doi-asserted-by":"publisher","unstructured":"Petrulioniene Z, Gargalskaite U, Mikstiene V, Norvilas R, Skiauteryte E, Utkus A. Autosomal recessive hypercholesterolemia: Case report. J Clin Lipidol [Internet]. 2019;13(6):887\u201393. https:\/\/doi.org\/10.1016\/j.jacl.2019.09.009.","DOI":"10.1016\/j.jacl.2019.09.009"},{"key":"2124_CR20","doi-asserted-by":"publisher","unstructured":"Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med [Internet]. 2019 Oct 17 [cited 2023 Aug 17];381(16):1547\u201356. https:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1816454.","DOI":"10.1056\/NEJMoa1816454"},{"issue":"2","key":"2124_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jacl.2015.12.019","volume":"10","author":"R Andersen","year":"2016","unstructured":"Andersen R, Andersen L. Examining barriers to cascade screening for familial hypercholesterolemia in the United States. J Clin Lipidol. 2016;10(2):225\u20137.","journal-title":"J Clin Lipidol"},{"key":"2124_CR22","doi-asserted-by":"publisher","unstructured":"Groselj U, Kovac J, Sustar U, Mlinaric M, Fras Z, Podkrajsek KT et al. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis [Internet]. 2018;277:383\u201391. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.858.","DOI":"10.1016\/j.atherosclerosis.2018.06.858"},{"issue":"9","key":"2124_CR23","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1194\/jlr.S074039","volume":"58","author":"AC Martin","year":"2017","unstructured":"Martin AC, Gidding SS, Wiegman A, Watts GF. Knowns and unknowns in the care of pediatric familial hypercholesterolemia. J Lipid Res. 2017;58(9):1765\u201376.","journal-title":"J Lipid Res"},{"key":"2124_CR24","unstructured":"Higienos institutas [Internet]. [cited 2024 Mar 23]. https:\/\/stat.hi.lt\/default.aspx?report_id=168."},{"issue":"11","key":"2124_CR25","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"M Benn","year":"2012","unstructured":"Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"2124_CR26","doi-asserted-by":"crossref","unstructured":"Degoma EM, Ahmad ZS, O\u2019Brien EC, Kindt I, Shrader P, Newman CB et al. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States. Circ Cardiovasc Genet [Internet]. 2016 Jun 1 [cited 2024 Apr 15];9(3):240\u20139. Available from: \/pmc\/articles\/PMC5315030\/.","DOI":"10.1161\/CIRCGENETICS.116.001381"},{"key":"2124_CR27","doi-asserted-by":"publisher","unstructured":"Knowles JW, O\u2019Brien EC, Greendale K, Wilemon K, Genest J, Sperling LS et al. Reducing the burden of disease and death from familial hypercholesterolemia: A call to action. Am Heart J [Internet]. 2014;168(6):807\u201311. https:\/\/doi.org\/10.1016\/j.ahj.2014.09.001.","DOI":"10.1016\/j.ahj.2014.09.001"},{"key":"2124_CR28","doi-asserted-by":"crossref","unstructured":"Marco-Bened\u00ed V, Laclaustra M, Casado-Dominguez JM, Villa-Pobo R, Mateo-Gallego R, S\u00e1nchez-Hern\u00e1ndez RM et al. Aortic valvular disease in elderly subjects with heterozygous familial hypercholesterolemia: impact of lipid-lowering therapy. J Clin Med. 2019;8(12).","DOI":"10.3390\/jcm8122209"},{"key":"2124_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.athplu.2022.08.001","volume":"50","author":"J Ferri\u00e8res","year":"2022","unstructured":"Ferri\u00e8res J, Farnier M, Bruckert E, Vimont A, Durlach V, Ferrari E, et al. Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia. Atheroscler Plus. 2022;50:17\u201324.","journal-title":"Atheroscler Plus"},{"key":"2124_CR30","doi-asserted-by":"crossref","unstructured":"Aliosaitiene U, Petrulioniene Z, Rinkuniene E, Mainelis A, Barysiene J, Smailyte U et al. Early atherosclerosis in familial hypercholesterolemia patients: significance of vascular markers for. Risk Stratification. 2024;1\u201313.","DOI":"10.21203\/rs.3.rs-3964470\/v1"},{"key":"2124_CR31","doi-asserted-by":"crossref","unstructured":"Catapano F, Galea N, Pambianchi G, D\u2019Erasmo L, Borrazzo C, Cundari G et al. Effectiveness of clinical scores in predicting coronary artery disease in familial hypercholesterolemia: a coronary computed tomography angiography study. Radiol Med [Internet]. 2023 Apr 1 [cited 2024 Apr 15];128(4):445. \/pmc\/articles\/PMC10119045\/","DOI":"10.1007\/s11547-023-01610-z"},{"issue":"3","key":"2124_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/clc.22881","volume":"41","author":"F S\u00e9guro","year":"2018","unstructured":"S\u00e9guro F, Rab\u00e8s JP, Taraszkiewicz D, Ruidavets JB, Bongard V, Ferri\u00e8res J. Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk. Clin Cardiol. 2018;41(3):385\u201391.","journal-title":"Clin Cardiol"},{"issue":"4","key":"2124_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","volume":"74","author":"M Trinder","year":"2019","unstructured":"Trinder M, Li X, DeCastro ML, Cermakova L, Sadananda S, Jackson LM, et al. Risk of premature atherosclerotic disease in patients with monogenic Versus Polygenic Familial Hypercholesterolemia. J Am Coll Cardiol. 2019;74(4):512\u201322.","journal-title":"J Am Coll Cardiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02124-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02124-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02124-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T08:04:44Z","timestamp":1715069084000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02124-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02124-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3897888\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Vilnius (Lithuania) regional bioethics committee, permit number 158200-18\/5-1010-538, issued in 2018.05.18. All the patients who were selected to be included in the Lithuanian long-term FH observation programme, as well as in the European Atherosclerosis Society Familial Hypercholesterolemia Studies Collaboration (EAS FHSC) global registry, signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}